Literature DB >> 18391992

Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT.

F Ostronoff, M-A Perales, M D Stubblefield, K C Hsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18391992      PMCID： PMC4445357          DOI： 10.1038/bmt.2008.81

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

Review 1.  Guillain-Barré syndrome.

Authors:  Richard A C Hughes; David R Cornblath
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

Review 2.  Treatment of dys-immune neuropathies.

Authors:  Eduardo Nobile-Orazio
Journal:  J Neurol       Date:  2005-04       Impact factor: 4.849

Review 3.  Neurological complications of organ transplantation.

Authors:  R A Patchell
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

Review 4.  Guillain-Barré syndrome following allogeneic bone marrow transplantation.

Authors:  P Y Wen; E P Alyea; D Simon; R S Herbst; R J Soiffer; J H Antin
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

5.  Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  V Rodriguez; I Kuehnle; H E Heslop; S Khan; R A Krance
Journal:  Bone Marrow Transplant       Date:  2002-03       Impact factor: 5.483

6.  Inflammatory peripheral neuropathy following high dose chemotherapy and autologous bone marrow transplantation.

Authors:  R M Bashir; P Bierman; R McComb
Journal:  Bone Marrow Transplant       Date:  1992-09       Impact factor: 5.483

Review 7.  Polyneuropathy complicating bone marrow and solid organ transplantation.

Authors:  A A Amato; R J Barohn; Z Sahenk; P J Tutschka; J R Mendell
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

8.  The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.

Authors:  Francesca Patriarca; Cristina Skert; Alessandra Sperotto; Francesco Zaja; Edmondo Falleti; Rosalba Mestroni; Francesca Kikic; Elisabetta Calistri; Carla Filì; Antonella Geromin; Michela Cerno; Renato Fanin
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

9.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

Review 10.  B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome.

Authors:  T G Gross; M Steinbuch; T DeFor; R S Shapiro; P McGlave; N K Ramsay; J E Wagner; A H Filipovich
Journal:  Bone Marrow Transplant       Date:  1999-02       Impact factor: 5.483
  10 in total
  9 in total

Review 1.  New strategies in the management of Guillain-Barré syndrome.

Authors:  Jinting Xiao; Alain R Simard; Fu-Dong Shi; Junwei Hao
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Jane Pritchard; Richard Ac Hughes; Robert Dm Hadden; Ruth Brassington
Journal:  Cochrane Database Syst Rev       Date:  2016-11-15

Review 3.  Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors:  Yusuf A Rajabally
Journal:  Neurotherapeutics       Date:  2022-06-01       Impact factor: 6.088

Review 4.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

5.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Alex Y Doets; Richard Ac Hughes; Ruth Brassington; Robert Dm Hadden; Jane Pritchard
Journal:  Cochrane Database Syst Rev       Date:  2020-01-25

6.  Guillain-Barré syndrome after allogeneic bone marrow transplantation: Case report and literature review.

Authors:  Tomoko Yoshida; Yoshino Ueki; Tomotaka Suzuki; Yuichi Kawagashira; Haruki Koike; Shigeru Kusumoto; Shinsuke Ida; Takuya Oguri; Masahiro Omura; Noriyuki Matsukawa
Journal:  eNeurologicalSci       Date:  2016-08-04

7.  [Paraplegia after hematopoietic stem cell transplantation].

Authors:  Y F Cheng; X J Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

Review 8.  Peripheral nerve disease secondary to systemic conditions in children.

Authors:  Jo M Wilmshurst; Robert A Ouvrier; Monique M Ryan
Journal:  Ther Adv Neurol Disord       Date:  2019-08-12       Impact factor: 6.570

Review 9.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.